Results 61 to 70 of about 535,314 (143)

Real-world experience with pro re nata dosing of intravitreal dexamethasone implant for eyes with refractory diabetic macular edema

GMS Ophthalmology Cases, 2020
Aims: To evaluate treatment outcomes of pro re nata dosing of intravitreal dexamethasone implant in eyes with refractory diabetic macular edema (DME) amongst Indian subjects.Methods and material: Retrospective, interventional case series. Medical records
Rishi, Pukhraj, Rishi, Ekta, Attiku, Yamini, Dhami, Abhinav, Iyer, Vandana   +4 more
doaj   +1 more source

Implantable drug delivery system: Frontiers of medicine‐engineering interdisciplinary

Interdisciplinary Medicine, Volume 4, Issue 4, July 2026.
This review systematically summarizes the driving mechanisms of implantable on‐demand drug delivery systems (IDDS), including endogenous, exogenous, and closed‐loop strategies. It highlights the pivotal roles of flexible electronics and miniaturization in enhancing the tissue conformity and spatial adaptability.
Yu Zeng, Rongtai Su, Manyu Zhao, Xin Song, Ran Liu, Yuhao Zhou, Chaojuan Yang, Yanli Jiao, Xiao‐Wei Xiang, Lingqian Chang   +9 more
wiley   +1 more source

Intraoperative Dexamethasone Intravitreal Implant (Ozurdex) in Vitrectomy Surgery for Epiretinal Membrane

, 2019
Objective: To study the effectiveness and safety of the intravitreal dexamethasone implant 0.7 mg (Ozurdex®) in vitrectomy surgery for epiretinal membrane. Methods: This is a prospective, multicenter, pilot study.
Avner Hostovsky (8106461), Drew Mulhall (8106467), Christina Leung (8106470), Rajeev H. Muni (7623494), Peter J. Kertes (8106473), Kenneth T. Eng (8106464)   +5 more
core   +1 more source

Anterior Chamber Dislocation of Dexamethasone Implant in the Presence of Carlevale Sutureless Scleral Fixation Intraocular Lens

Case Reports in Ophthalmology, 2023
Dexamethasone intravitreal implant (Ozurdex®; Allergan, Inc., CA, USA) has been proved to be effective in a variety of clinical settings including cases of pseudophakic cystoid macular edema.
Panagiotis Stavrakas, Panos Gartaganis, Styliani Totou, Evangelia Chalkiadaki, Evangelos Manousakis, Efthymios Karmiris   +5 more
doaj   +1 more source

Current Landscape and Future Perspectives of Diabetic Retinopathy Therapy: Pharmacological Targets, Precision Laser Technology, and Clinical Evidence

MedComm, Volume 7, Issue 7, July 2026.
Targeted biological agents targeting VEGF, integrin, dopamine D2 receptor, ROCK, and BCL‐XL have entered the clinical trial phase and deserve particular attention. The treatment paradigm has shifted toward personalized and precision medicine, positioning optimized SML as a promising adjunctive therapy.
Xinying Hu, Zhe Cha, Ao Lu, Wuping Xu, Xiaoqing Zhang, Sheng Miao, Haiwei Xu, Xuedong Xu   +7 more
wiley   +1 more source

Rhegmatogenous Retinal Detachment with a High Risk of Proliferative Vitreoretinopathy Treated with Episcleral Surgery and an Intravitreal Dexamethasone 0.7-mg Implant

Case Reports in Ophthalmology, 2013
Purpose: To report a case of rhegmatogenous retinal detachment with a high risk of proliferative vitreoretinopathy (PVR) effectively treated with episcleral surgery and an intravitreal dexamethasone 0.7-mg implant.
Michele Reibaldi, Andrea Russo, Antonio Longo, Vincenza Bonfiglio, Maurizio G. Uva, Caterina Gagliano, Mario D. Toro, Teresio Avitabile   +7 more
doaj   +1 more source

Anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule

American Journal of Ophthalmology Case Reports, 2020
Purpose: To describe a case of spontaneous anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule.
Manal Alzaabi, Abdel Hakim Taguri, Ahmed Elbarky   +2 more
doaj   +1 more source

Sustained-release Intravitreal Dexamethasone (Ozurdex®) Implant as a Surgical Adjuvant in High-risk Proliferative Vitreoretinopathy

Journal of Ophthalmological Society of West Bengal
The purpose of the study was to evaluate the efficacy of Sustained-release Intravitreal Dexamethasone implant (Ozurdex; Allergan Inc., Irvine, CA) during vitrectomy in preventing proliferative vitreoretinopathy (PVR).
S. Ganekal, S. Dorairaj
semanticscholar   +1 more source

Smart Polymer‐Based Drug Delivery Systems for Managing Infective Conjunctivitis: Advances and Future Prospects

Nano Select, Volume 7, Issue 6, June 2026.
The introduction covers the background and significance of conjunctivitis. It continues with a review of etiology, epidemiology, and clinical manifestations. Diagnostic methods are described, followed by discussions on pathophysiology and classification. Current treatment strategies, preventive measures, and therapeutic challenges are analyzed.
Xia Linkang, Marwan Abdelmahmoud Abdelkarim Maki, Saad Tayyab, Sachin Thakur, Pankaj Kumar, Ritu Karwasra, Mahesh Harihar Behare, Nitin Sharma, Wan Hamirul Bahrin Wan Kamal, Oganeswary Kobi, Kushagra Khanna, Mogana Rajagopal   +11 more
wiley   +1 more source

Postintravitreal Dexamethasone Implant (OZURDEX®) – Induced Ocular Hypotony in Patients with Rheumatological Disease: A Rare Complication

Journal of Ophthalmology Clinics and Research
Dexamethasone intravitreal implant (OZURDEX ® ) is widely used in the management of inflammatory and edematous ocular conditions, including those associated with systemic rheumatological diseases. While generally considered safe, rare complications
Jayamadhury Gudimetla, R. Madhukumar, Tata Monika, K. Padma   +3 more
semanticscholar   +1 more source